Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The addition of RAD001, an mTOR inhibitor, to irinotecan and anti-EGFR antibody cetuximab may
increase efficacy for patients with metastatic colorectal cancer who progressed on prior
chemotherapy. This approach is biologically directed to overall target the cancer cell at
multiple levels, and potentially preventing chemotherapy and EGFR-therapy resistance.